2
Registered trials
0
Recruiting
2
Unique sponsors
1
Unique IMPs
2
Commercial trials
Drug classes (ATC)
L
Oncology (ATC L)
1
S
Ophthalmology/ENT (ATC S)
1
Mechanism of action (INN-stem analysis)
Receptor fusion protein
1 substance
Phase III:
2
Phase III
2 trials-
EndedAlvotech Swiss AG CommercialAFLIBERCEPT
-
EndedBayer AG CommercialAFLIBERCEPT
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Alvotech Swiss AG | Commercial | 1 | Phase III | 0 |
| Bayer AG | Commercial | 1 | Phase III | 0 |
New trials by year
2023
1
2024
1